Regulation And Metabolic Functions Of mTORC1 And mTORC2
Research Summary
A large narrative review of the two protein complexes built around the mTOR kinase. It covers how mTORC1 and mTORC2 are switched on, how their parts are regulated, which proteins they act on, and how they reprogram cell metabolism. Most of the evidence comes from cancer models, with sections on stem cells, immune cells, type 2 diabetes and obesity, neurodegenerative disorders and ageing.
Who Or What Was Studied?
Published research in yeast, flies, worms, mice, cultured cells and humans on mTOR signalling and metabolism. The review does not report new experiments or new data.
What Did The Research Show?
- mTORC1 is directly and allosterically inhibited by rapamycin, while mTORC2 is not directly inhibited; structural studies show that part of the rictor protein blocks the rapamycin binding site in mTORC2.
- mTORC1 is mainly activated by amino acids and growth factors at the surface of lysosomes, through Rag GTPases and Rheb. mTORC2 responds to growth factor (PI3K) signals and to changes in nutrient levels, and phosphorylates Akt, PKC and SGK.
- Both complexes steer metabolism: mTORC1 promotes glycolysis through HIF1α and Myc, and supports protein, nucleotide and lipid synthesis, while it suppresses autophagy.
- In mouse models of Alzheimer’s disease, rapamycin or genetic reduction of mTOR signalling reduced amyloid-β deposits, tau phosphorylation and tangles, and improved cognitive measures.
- Lowering mTORC1 activity is linked to longer life span in several species, and S6K1-deficient mice live longer. In contrast, loss of rictor (mTORC2) in the liver or the whole body shortened life span in male but not female mice, loss in the hypothalamus also shortened life span, and prolonged rapamycin treatment that lowers mTORC2 signalling impaired glucose and lipid balance.
Limitations And Interpretation
- A narrative review, not a systematic review: the authors chose which studies to discuss, and no new data were collected.
- Much of the evidence comes from cancer cells and animal models, so it cannot be applied directly to healthy people.
- The authors note that mTORC2 is much less understood than mTORC1, partly because there is no drug that blocks mTORC2 specifically.
- The review stresses that the right level of mTOR activity matters: in some conditions, such as models of Parkinson’s and Huntington’s disease, raising mTOR activity also had protective effects.
Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.